Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol vs Metoprolol Glycemic Control in Hypertensive Type 2 Diabetics
NCT00060918Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2001
- Primary completion
- Apr 2004
- Countries
- 1
- Sponsor
- GSK
- Modality
- Small Molecules
- Drugs
- carvedilol
- Conditions
- hypertension (HTN)
01
Overview
Phase 4, randomised, double-blind trial of carvedilol in hypertension (HTN) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in HbA1c at 5 months. Started Jun 2001; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Carvedilol
Carvedilol + ACE/ARB
Metoprolol
Metoprolol + ACE/ARB
03
Who it enrols
Hypertensive patients with Type 2 diabetes on stable ACE/ARB therapy, with HbA1c 6.5-8.5% (drug treated) or 6.5-7.5% (diet alone).
04
Endpoints
Primary
Change from baseline in HbA1c
Secondary
Blood pressure
Body weight
Laboratory values
Beyond the preview
Go deeper on NCT00060918.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060918.